Impetigo
Impetigo is a highly contagious, superficial bacterial skin infection most commonly affecting children aged 2-5 years. It is the most common bacterial skin infection in children worldwide, caused primarily by Staphylococcus aureus and Streptococcus pyogenes. The infection presents as honey-colored crusted lesions or bullae, typically on the face, arms, and legs. While generally self-limiting, prompt treatment reduces transmission and prevents complications.
Clinical Pearls:
- Most common bacterial skin infection in children
- Peak incidence: 2-5 years, more common in warm, humid climates
- Highly contagious: Spreads through direct contact or fomites
- Two main types: Non-bullous (70%) and bullous (30%)
- Self-limiting but treatment reduces duration and transmission
Red Flags:
- Staphylococcal scalded skin syndrome: Widespread erythema and desquamation
- Cellulitis: Spreading erythema, warmth, systemic symptoms
- Post-streptococcal glomerulonephritis: Hematuria, hypertension, edema
- Systemic symptoms: Fever, lymphadenopathy, malaise
- Ecthyma: Deep ulcerative form with scarring
Impetigo is a global health problem, particularly in resource-limited settings and tropical climates. The true incidence is underestimated due to underreporting and self-treatment.
Key Statistics:
- Global incidence: 140-200 million cases annually
- Peak age: 2-5 years (50-60% of cases)
- Seasonal variation: Higher in summer and rainy seasons
- Prevalence: 1-2% of children in developed countries
- Endemic areas: Up to 10-20% prevalence in tropical regions
Risk Factors Distribution:
- Age: 70% of cases in children less than 10 years
- Gender: Slight male predominance (1.2:1)
- Geography: Higher in tropical and subtropical regions
- Socioeconomic: More common in overcrowded, poor hygiene conditions
- Climate: Warm, humid weather increases transmission
Mortality and Morbidity:
- Mortality: Rare, less than 0.1% (usually from complications)
- Complications: 2-5% develop cellulitis or deeper infections
- Post-streptococcal glomerulonephritis: 1-5% in endemic areas
- Recurrence: 20-30% within 6 months without proper hygiene
Impetigo results from bacterial invasion of the superficial epidermis through breaks in skin integrity. The pathogenesis involves bacterial adhesion, toxin production, and local inflammatory responses.
Pathophysiology Steps:
-
Skin Barrier Disruption: Minor trauma, insect bites, eczema, or other skin conditions create entry points for bacteria to penetrate the stratum corneum
-
Bacterial Colonization: Staphylococcus aureus or Streptococcus pyogenes colonize the disrupted skin, adhering to epithelial cells via surface proteins (M protein in Strep, protein A in Staph)
-
Toxin Production: S. aureus produces exfoliative toxins (ETA, ETB) causing acantholysis and bulla formation in bullous impetigo, while both organisms produce various virulence factors
-
Epidermal Invasion: Bacteria multiply in the superficial epidermis, causing local tissue damage and triggering inflammatory responses
-
Inflammatory Response: Neutrophil recruitment and activation lead to pus formation, characteristic of impetigo lesions
-
Lesion Formation: Non-bullous: Vesicles rupture, form honey-colored crusts. Bullous: Flaccid bullae from toxin-mediated acantholysis
-
Spread and Transmission: Autoinoculation spreads infection to adjacent areas, while direct contact or fomites transmit to others, maintaining the infection cycle
Non-Modifiable Risk Factors:
- Age: Peak incidence 2-5 years due to immature immune system and close contact
- Genetic factors: Certain HLA types may increase susceptibility
- Atopic dermatitis: 2-3 fold increased risk due to skin barrier dysfunction
- Climate: Warm, humid conditions favor bacterial growth
Modifiable Risk Factors:
- Poor hygiene: Inadequate handwashing and bathing
- Crowded living conditions: Increases person-to-person transmission
- Skin trauma: Cuts, abrasions, insect bites provide entry points
- Nasal carriage: S. aureus nasal colonization increases risk
- Underlying skin conditions: Eczema, scabies, varicella
Environmental Factors:
- Warm, humid climate: Promotes bacterial growth
- Poor sanitation: Contaminated water, inadequate waste disposal
- Shared facilities: Schools, daycares, sports facilities
- Seasonal: Higher incidence in summer months
Protective Factors:
- Good personal hygiene: Regular handwashing, bathing
- Intact skin barrier: Moisturization, avoiding trauma
- Prompt treatment: Early intervention reduces spread
- Isolation: Keeping lesions covered reduces transmission
Clinical features vary by type and severity. Non-bullous impetigo is more common and presents with characteristic honey-colored crusts, while bullous impetigo shows flaccid bullae.
Non-Bullous Impetigo (70%):
Bullous Impetigo (30%):
Ecthyma (Deep Form):
Systemic Features:
Complications:
Clinical diagnosis is usually straightforward based on characteristic appearance. Examination should assess extent, type, and complications.
Visual Inspection:
- Lesion morphology: Honey-colored crusts (non-bullous) or flaccid bullae (bullous)
- Distribution: Face, extremities, or widespread
- Number: Count lesions to guide treatment approach
- Surrounding skin: Erythema, warmth, induration suggesting cellulitis
Palpation:
- Consistency: Crusts are adherent, bullae are flaccid
- Temperature: Warmth suggests deeper infection
- Tenderness: Usually minimal unless complicated
- Regional lymph nodes: Enlarged, tender nodes common
Special Assessments:
- Nikolsky sign: Negative (distinguishes from pemphigus)
- Tzanck smear: Not typically needed, shows acantholytic cells if done
- Wood's lamp: Not helpful (no fluorescence)
Key Findings:
- Honey-colored crusts: Pathognomonic for non-bullous impetigo
- Flaccid bullae: Characteristic of bullous impetigo
- Regional lymphadenopathy: Common, especially with Strep
- Absence of systemic symptoms: Distinguishes from deeper infections
Diagnosis is usually clinical. Investigations are reserved for atypical presentations, treatment failures, or suspected complications.
Clinical Diagnosis:
- Usually sufficient based on characteristic appearance
- History: Rapid onset, contact with affected individuals
- Examination: Typical honey-colored crusts or bullae
Microbiological Testing:
- Swab culture: Reserved for treatment failures, complications, or outbreaks
- Gram stain: Shows Gram-positive cocci in clusters (Staph) or chains (Strep)
- Sensitivity testing: Important for resistant cases or MRSA
Rapid Tests:
- Strep A rapid test: Available but not routinely needed
- Point-of-care tests: Emerging but not standard
Advanced Investigations:
- Blood cultures: If systemic symptoms or suspected bacteremia
- Complete blood count: If systemic symptoms present
- Renal function: If post-streptococcal GN suspected
- ASO titers: For retrospective diagnosis of Strep infection
Differential Diagnosis Considerations:
| Condition | Distinguishing Features |
|---|---|
| Herpes simplex | Grouped vesicles, recurrent, painful |
| Varicella | Widespread, different stages, systemic symptoms |
| Contact dermatitis | Pruritic, history of exposure, no crusts |
| Tinea corporis | Scaling, central clearing, KOH positive |
| Eczema herpeticum | Grouped vesicles, history of eczema |
| Pemphigus | Positive Nikolsky, acantholytic cells on smear |
Management depends on extent, type, and patient factors. Topical treatment suffices for limited disease, while widespread or bullous impetigo requires systemic antibiotics.
IMPETIGO MANAGEMENT ALGORITHM
==============================
Patient presents with impetigo
|
v
Assess Extent and Type
|
+-------------------+-------------------+
| | |
LIMITED DISEASE WIDESPREAD/BULLOUS COMPLICATED
(less than 5 lesions, (>5 lesions, (Cellulitis,
non-bullous) bullous, or systemic symptoms,
extensive) lymphangitis)
| | |
Topical Treatment Oral Antibiotics Hospital Assessment
| | |
- Mupirocin 2% - Flucloxacillin - IV antibiotics
tds x 5-7 days 500mg qds x 7 days - Blood cultures
- Fusidic acid - Clarithromycin - Wound care
2% tds x 5-7 if penicillin - Supportive care
- Retapamulin allergic
1% bd x 5 days - Co-amoxiclav
- Ozenoxacin 1% if MRSA suspected
bd x 5 days |
Assess Response
at 48-72 hours
|
+-------------------+
| |
Improved No Improvement
| |
Continue course - Review diagnosis
Cover lesions - Consider resistance
Hygiene advice - Change antibiotic
- Consider swab
PREVENTION AND HYGIENE
|
+-------------------+-------------------+
| | |
Personal Hygiene Environmental School/Work
| | |
- Handwashing - Clean surfaces - Exclude until
- Cover lesions - Wash bedding crusted or
- Avoid scratching - Hot wash towels 48h antibiotics
- Separate towels - Disinfect toys - Cover lesions
- Nail trimming - Good ventilation - Hand hygiene
FOLLOW-UP
|
v
Review at 48-72 hours if no improvement
Complete full antibiotic course
Monitor for complications
Educate on prevention
Topical Treatment (Limited Disease):
First-Line Options:
- Mupirocin 2%: Apply tds for 5-7 days, 90% cure rate
- Fusidic acid 2%: Apply tds for 5-7 days, good efficacy
- Retapamulin 1%: Apply bd for 5 days, newer agent
- Ozenoxacin 1%: Apply bd for 5 days, good for resistant cases
Application:
- Clean lesions with soap and water, remove crusts
- Apply thin layer to affected areas and 1cm beyond
- Cover with non-stick dressing if possible
- Wash hands after application
Oral Treatment (Widespread/Bullous):
First-Line:
- Flucloxacillin: 500mg qds for 7 days (adults), 12.5-25mg/kg qds (children)
- Co-amoxiclav: 625mg tds if MRSA suspected
- Clarithromycin: 250-500mg bd if penicillin allergic
Dosing:
- Adults: Standard doses
- Children: Weight-based dosing
- Duration: 7 days typically sufficient
- Compliance: Important for prevention of resistance
Special Considerations:
- MRSA: Consider doxycycline, clindamycin, or co-trimoxazole
- Pregnancy: Topical mupirocin preferred, oral erythromycin if needed
- Neonates: Require systemic treatment, consider hospital admission
While impetigo is usually self-limiting, complications can occur, particularly with delayed treatment or in high-risk individuals.
Local Complications:
Cellulitis:
- Incidence: 2-5% of cases
- Presentation: Spreading erythema, warmth, induration
- Management: Oral or IV antibiotics, close monitoring
- Risk factors: Delayed treatment, extensive disease, immunosuppression
Lymphangitis:
- Red streaks extending proximally from lesions
- Tender, enlarged regional lymph nodes
- Requires systemic antibiotic treatment
- Usually resolves with appropriate therapy
Ecthyma:
- Deep ulcerative form extending into dermis
- More common in immunosuppressed or malnourished
- Slower healing, may cause scarring
- Requires longer antibiotic course
Systemic Complications:
Staphylococcal Scalded Skin Syndrome:
- Rare but serious complication
- Widespread erythema and desquamation
- Caused by exfoliative toxins
- Requires hospital admission and IV antibiotics
Post-Streptococcal Glomerulonephritis:
- Incidence: 1-5% in endemic areas, rare in developed countries
- Onset: 1-2 weeks after infection
- Presentation: Hematuria, hypertension, edema, proteinuria
- Management: Supportive, usually self-limiting
- Prevention: Early treatment may reduce risk
Bacteremia:
- Rare complication
- More common in neonates or immunosuppressed
- Requires blood cultures and IV antibiotics
- Can lead to metastatic infections
Chronic Complications:
- Scarring: Uncommon but can occur with ecthyma
- Recurrence: 20-30% within 6 months
- Psychosocial: Stigma, school absence, social isolation
Excellent prognosis with appropriate treatment. Most cases resolve completely without sequelae.
Treatment Outcomes:
- Topical treatment: 85-95% cure rate within 5-7 days
- Oral treatment: 90-95% cure rate within 7 days
- Time to resolution: 5-10 days with treatment, 2-3 weeks without
- Scarring: Rare except with ecthyma
Natural History:
- Without treatment: Self-limiting in 2-3 weeks
- With treatment: Resolution in 5-10 days
- Recurrence: 20-30% within 6 months
- Complications: less than 5% with appropriate treatment
Factors Affecting Prognosis:
- Early treatment: Better outcomes, reduced transmission
- Compliance: Essential for cure and prevention of resistance
- Hygiene: Good hygiene reduces recurrence
- Underlying conditions: Immunosuppression increases complication risk
Long-term Considerations:
- Most resolve without sequelae
- Post-streptococcal GN: Usually self-limiting, rare chronic kidney disease
- Recurrence prevention: Hygiene education important
- Quality of life: Minimal impact with prompt treatment
Major Guidelines:
- NICE Clinical Knowledge Summary (CKS): Impetigo management guidelines
- American Academy of Dermatology (AAD): Guidelines for impetigo treatment
- Infectious Diseases Society of America (IDSA): Skin and soft tissue infection guidelines
- European Dermatology Forum: Evidence-based treatment recommendations
Landmark Clinical Trials:
-
Cochrane Review (2012): Interventions for impetigo
- Topical antibiotics more effective than placebo
- Mupirocin equivalent to oral antibiotics for limited disease
- Fusidic acid effective but resistance concerns
- PMID: 22258953
-
Ozenoxacin Trials (2019): Topical ozenoxacin for impetigo
- Non-inferior to retapamulin
- Good safety profile
- Effective against resistant strains
- PMID: 31334625
-
Retapamulin Studies (2007): Topical retapamulin efficacy
- Superior to placebo
- Effective for MRSA impetigo
- Well-tolerated, minimal resistance
- PMID: 17558424
-
Mass Drug Administration Studies (2021): Endemic impetigo control
- Mass treatment reduces community prevalence
- Effective public health strategy
- Reduces complications including post-streptococcal GN
- PMID: 34184743
-
Antimicrobial Resistance Studies (2021): Treatment algorithm development
- Resistance patterns guide treatment selection
- MRSA considerations important
- Regional resistance patterns vary
- PMID: 33538559
Meta-Analyses:
- Topical vs oral antibiotics: Topical sufficient for limited disease (Koning, 2012)
- Treatment duration: 5-7 days typically adequate (Schachner, 2020)
- Prevention strategies: Hygiene and early treatment reduce transmission (Hall, 2022)
Systematic Reviews:
- Impetigo treatment: Comprehensive review of evidence (Schachner, 2021)
- Endemic settings: Mass treatment strategies effective (Bowen, 2015)
- Pediatric management: Consensus recommendations (Schachner, 2020)
"What is impetigo?" Impetigo is a common, contagious skin infection that causes sores and blisters, usually on the face, arms, or legs. It's most common in young children and is caused by bacteria. The sores look like honey-colored crusts or blisters that ooze and then form scabs.
"How did my child get it?" Impetigo spreads easily through direct contact with someone who has it, or by touching things they've touched (like towels or toys). It can also start when bacteria get into small breaks in the skin from cuts, scrapes, or insect bites. It's very common in children because they play closely together and may not wash hands as often.
"What symptoms will I see?" You'll notice sores that start as small blisters or red spots, then form honey-colored, golden-yellow crusts. They're usually around the nose, mouth, or on the arms and legs. Sometimes there are larger blisters that look like they're filled with water. The sores may itch a bit but usually don't hurt much.
"How is it treated?" For small areas, your doctor will give you a cream or ointment to put on the sores. You'll apply it 2-3 times a day for about a week. For more widespread infection or if there are blisters, your doctor may prescribe antibiotic pills. It's important to finish all the medicine, even if the sores look better.
"How do I apply the cream?" First, gently wash the sores with soap and water and remove any crusts. Then apply a thin layer of the cream to the sores and a little bit of the skin around them. Wash your hands well after applying. You can cover the sores with a bandage to prevent spreading.
"Is it contagious?" Yes, very contagious! Your child should stay home from school or daycare until the sores are crusted over or they've been on antibiotics for 48 hours. Don't share towels, washcloths, or clothing. Wash bedding and clothes in hot water.
"How long until it's better?" With treatment, the sores usually start looking better in 2-3 days and are mostly healed within a week. Without treatment, it can take 2-3 weeks. Make sure to finish all the medicine your doctor prescribed.
"Can it come back?" It can come back, especially if hygiene isn't good or if your child is around others with impetigo. To prevent it, make sure your child washes hands regularly, keeps nails trimmed, and doesn't share personal items. If someone in the family gets it, everyone should be extra careful about hygiene.
"When should I worry?" Call your doctor if:
- The sores spread or get worse after starting treatment
- Your child develops a fever
- The skin around the sores becomes red, warm, or painful
- Your child seems very sick
- Sores don't start improving after 3-4 days of treatment
"Can I prevent it?" Yes! Teach your child to wash hands regularly, especially after playing. Keep cuts and scrapes clean and covered. Don't share towels, clothing, or personal items. If someone has impetigo, make sure they get treatment right away and keep their sores covered.
-
Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;(1):CD003261. PMID: 22258953
-
Schachner LA, Lynde CW, Kircik LH, et al. Treatment of Impetigo and Antimicrobial Resistance. J Drugs Dermatol. 2021;20(4):374-380. PMID: 33852242
-
Hall LM, Gorges HJ, van Driel M, et al. International comparison of guidelines for management of impetigo: a systematic review. Fam Pract. 2022;39(1):84-92. PMID: 34184743
-
Schachner LA, Torrelo A, Grada A, et al. Treatment of Impetigo in the Pediatric Population: Consensus and Future Directions. J Drugs Dermatol. 2020;19(3):268-276. PMID: 32550690
-
Schachner L, Andriessen A, Bhatia N, et al. Topical Ozenoxacin Cream 1% for Impetigo: A Review. J Drugs Dermatol. 2019;18(7):655-661. PMID: 31334625
-
Schachner LA, Andriessen A, Benjamin LT, et al. Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo. J Drugs Dermatol. 2021;20(2):134-142. PMID: 33538559
-
Loadsman MEN, Verheij TJM, van der Velden AW. Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data. Fam Pract. 2019;36(4):410-416. PMID: 30346521
-
Bowen AC, Mahé A, Hay RJ, et al. The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PLoS One. 2015;10(8):e0136789. PMID: 26317533
-
Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis. 2015;15(8):960-967. PMID: 26088526
-
Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J Paediatr Child Health. 2007;43(4):203-213. PMID: 17444824
-
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):e10-e52. PMID: 24973422
-
Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):859-864. PMID: 17390597
-
Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90(4):229-235. PMID: 25250996
-
Koning S, Verhagen AP, van Suijlekom-Smit LW, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2004;(2):CD003261. PMID: 15106198
-
Dajani AS, Ferrieri P, Wannamaker LW. Natural history of impetigo. II. Etiologic agents and bacterial interactions. J Clin Invest. 1972;51(11):2863-2871. PMID: 5080417
-
Dajani AS, Wannamaker LW, Ferrieri P. Natural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. J Clin Invest. 1973;52(4):908-916. PMID: 4693658
-
Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis. 2002;22:42-51. PMID: 12520646
-
Sladden MJ, Johnston GA. Common skin infections in children. BMJ. 2004;329(7457):95-99. PMID: 15242917
-
Darmstadt GL, Lane AT. Impetigo: an overview. Pediatr Dermatol. 1994;11(4):293-303. PMID: 7899178
-
George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003;53(491):480-487. PMID: 12879861